Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Summary not available.
Summary not available.
Summary not available.
AptarGroup, Inc. (NYSE:ATR) reported a strong third quarter for 2020, with sales increasing by 8% to $759 million, driven by currency effects and recent acquisitions. The Pharma segment saw core sales growth of 11%, while Beauty + Home and Food + Beverage segments experienced slower growth, impacted by COVID-19. Reported earnings per share rose 12% to $0.95. Year-to-date sales were stable at $2.18 billion. The company anticipates continued core sales growth in Q4, expecting EPS between $0.84 and $0.92. A quarterly dividend of $0.36 per share was declared, payable November 18, 2020.
AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.36 per share, with a payment date set for November 18, 2020 for shareholders on record as of October 28, 2020. Additionally, the company plans to hold a conference call on October 30, 2020, at 8:00 a.m. Central Time to discuss its third-quarter results for 2020. Investors can access a live webcast on the company's Investor Relations page.